SOURCE: CZ BioMed Corp

January 25, 2012 12:12 ET

Prostate Cancer Trials Underway Overseas PRO-RVLYSIN® CZ BioMed Corp.

TAMPA, FL--(Marketwire - Jan 25, 2012) - CZ BioMed Corp. announced today the successful collaboration with the Florida based Prostate Cancer Prevention Foundation (PCPF), allowing overseas trials of CZ BioMed's new treatment for prostate cancer, PRO-RVLYSIN®. PCPF has assisted by sponsoring treatments for 15 overseas patients which are already underway as of this writing.

PRO-RVLYSIN® is the invention of CZ BioMed Corp. PRO-RVLYSIN® is a novel, genetically engineered common cold-like virus that selectively kills only the Prostate cancer cells, while leaving the normal and healthy cells within the body unharmed. This is considered an oncolytic virotherapy systemic treatment, administered non-invasively through an I.V., which allows the PRO-RVLYSIN® to proceed on its search and destroy mission for cancer cells and is completely safe.

Traditional treatments combine surgery (removal of the prostate), chemo and radiation therapy, along with hormone blockers. Side effects usually involve incontinence and permanent impotence and/or dysfunction. Complete castration as a result of these treatments failing is a final option. These side effects are terrifying for men, and for many, unacceptable. PRO-RVLYSIN® so far has not shown to have any of these side effects.

The results from the 15 patients currently undergoing treatment will be forthcoming, but appear to be very promising thus far. The main benefits witnessed thus far include: safer treatment source, I.V. administration, and no side effects such as castration or erectile dysfunction. This means that men may no longer have to tackle these fears and compromise such dignities in the name of survival.

Prostate cancer is the most common malignancy and the second leading cause of cancer mortality amongst men in the Western world. In the USA, there is an estimated incidence of 217,730 cases and 32,050 deaths in 2010. Up to 40% of men diagnosed with prostate cancer will eventually develop metastatic disease, and although most respond to initial medical or surgical castration, progression to castration resistance is universal. The average survival for patients with castration-resistant prostate cancer is 2-3 years. It continues to be a major cause of cancer related morbidity and mortality, and there is an urgent need for new treatments.

"We are thankful to have the assistance and resources of the Prostate Cancer Prevention Foundation. This has allowed us to accelerate our overseas clinical trials schedule. Length of time to market may be the biggest hurdle patients have when awaiting new therapies. We are confident that our findings overseas, treating prostate cancer patients, will greatly bolster our efforts to expedite FDA trials and acceptance here in the U.S. Bringing one treatment to market may also help to fast-track our cures for other deadly cancers."
Calvin Cao, Chairman / CEO / President of CZ BioMed Corp.

About CZ BioMed Corp:

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells. The mission of CZ BioMed Corp. is rooted in the knowledge of our invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people's lives, we accept only the highest ethical and quality standards, both from ourselves and others.

For further information about CZ BioMed Corp. please visit: or call 813-600-4088

About Prostate Cancer Prevention Foundation:

The Prostate Cancer Prevention Foundation is dedicated to outreach through offering free educational talks and seminars to the community, low or no-cost PSA testing, and support for patients and their families. (per their website below)

For further information about Prostate Cancer Prevention Foundation (PCPF) please visit:

Forward Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.


Contact Information

    CZ BioMed Corp
    Phone: 813-600-4088